Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
FY 2025/26 results in line with preliminary figures released on 16 April: Record commercial performance, challenging execution on some rolling stock contracts, cash in line with guidance Record order...
-
Meudon (France), May 13th, 2026 Vallourec, a world leader in premium seamless tubular solutions, announces today its results for the first quarter 2026. The Board of Directors of Vallourec SA,...
-
LODI, Calif., May 12, 2026 (GLOBE NEWSWIRE) -- Farmers & Merchants Bancorp (OTCQX: FMCB) (the “Company” or “FMCB”), the parent company of Farmers & Merchants Bank of Central California (the...
-
C-BEYOND Phase 3 North American Trial for Treatment of Hepatitis C Virus (HCV) Remains on Track with Topline Results Expected Mid-2026 C-FORWARD Phase 3 Trial Outside North America for Treatment of...
-
SEATTLE, May 12, 2026 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced the presentation...
-
NEW YORK, May 12, 2026 (GLOBE NEWSWIRE) -- Titan Partners, a division of American Capital Partners ("Titan Partners" or "Titan"), is pleased to announce the appointments of Scott Buck, Kyle Bauser,...
-
On track for planned IND submission in mid-2026 and Phase 1 initiation in the second half of 2026 for XTX501, a potential best-in-class bispecific PD-1 / masked IL-2 Presented new preclinical data...
-
Monthly Highlights Bitcoin: Production increased 372% Y/Y to 783 BitcoinSEALMINERs: SEALMINER A4 series mass production launched with industry leading efficiency of 9.45 J/TColocation: Executing on...
-
BRISBANE, Australia, May 12, 2026 (GLOBE NEWSWIRE) -- North American lithium producer Elevra Lithium Limited (“Elevra or Company”) (ASX:ELV; NASDAQ:ELVR) announced today the outcomes of an Updated...
-
Pivotal Phase 2 with lasme-cel in r/r B-ALL (BALLI-01 trial) Pivotal Phase 2 first interim analysis expected in Q4 2026BLA submission anticipated in 2028 Phase 1 with eti-cel in r/r NHL (NATHALI-01...